

Project Centipede

## Exit Recommendation (M&A vs. IPO vs. SPAC)

August 18, 2023

## SUMMARY AND RECOMMENDATION

# Exit Strategy Recommendation

Given Centipede's Strong Revenue Growth, It Should Pursue an IPO

**Acquisition Offers****Cardinal's Offers Do Not Give Full Credit for Centipede's Future Growth Potential**

- Although Cardinal's "Offer A" is based on a 5.0x CY 25 TEV / Revenue multiple, 37% of the purchase price is deferred and linked to Earnouts, an Escrow, and a Management Retention Pool
- If none of these is paid out, the upfront multiple is 3.3x; with the two Earnouts and the Escrow, it's 4.3x multiple vs. a 4.4x median from the public comps
- Both Offer A and B are 90% Stock, so the investor payouts will be delayed even if Centipede qualifies for all the deferred payment components

**Strategic Alternatives****An IPO Would Maximize Centipede's Long-Term Value**

- The median 2-year forward revenue multiple from the comparable public companies is 4.4x, but we believe that Centipede could trade in the 3.5x – 6.5x range due to its premium growth rate
- An IPO would also give Centipede the currency to expand organically and via add-on acquisitions

**Recommendation****We Recommend Preparing for an IPO, with a SPAC Deal as a "Plan B"**

- Historically, IPOs have delivered superior performance, but a SPAC / reverse merger presents certain advantages, such as speed and reduced regulatory burden
- Efforts could be made to renegotiate Cardinal's offer, but we believe a higher price is unlikely, given the poor EPS accretion / dilution figures over the projected period

OPERATING MODEL AND VALUATION

# Summary of Operational Forecasts


Comparison of Operational Metrics and KPIs in Forecast Period Intervals

(All Metrics Represent Figures in FY 28 – Final Projected Year in Forecast)

	Downside Case	Base Case	Upside Case
Customer Count	▪ 91K	▪ 116K	▪ 137K
Revenue (CAGR)	▪ \$712 million (19%)	▪ \$1.0 billion (27%)	▪ \$1.4 billion (33%)
Average Billings	▪ \$9K	▪ \$10K	▪ \$12K
EBIT (Margin)	▪ \$119 million (17%)	▪ \$161 million (15%)	▪ \$201 million (15%)
Unlevered FCF	▪ \$104 million	▪ \$152 million	▪ \$209 million
DCF Implied Value	▪ \$1.4 – \$1.6 billion	▪ \$2.4 – \$2.8 billion	▪ \$3.4 – \$4.1 billion

# Valuation Summary

“Offer A” vs. Implied Values Based on Management Plan & Consensus Forecasts<sup>(1)(2)</sup>



(1) Market data based on closing prices as of 8/18/2023.  
(2) Consensus forecasts based on Capital IQ data as of 8/18/2023.

# Summary of Centipede Valuation Assumptions

Cardinal's Offers Are Reasonable, But Below the Likely IPO Valuation

The Comparable Public Companies and DCF Both Point to a Similar Valuation Range

## #1 Implied Valuation

Centipede's likely valuation is an Enterprise Value between \$2 and \$3 billion, a range that corresponds to the "Base Case" output of the DCF and the range of values implied by the comparable public companies

## #2 Comparable Public Companies

A set of U.S.-based SaaS public companies with CY 22 revenue between \$100 and \$500 million and revenue growth between 30% and 60% implies a Centipede TEV between \$1.5 and \$3.5 billion based on the projected revenue and EBITDA multiples

## #3 Discounted Cash Flow (DCF) Analysis

The DCF, based on an initial Discount Rate of 12.0% declining to 10.0%, declining revenue growth rates, and increasing margins into the Terminal Period, produces an Implied Enterprise Value between \$2.4 and \$2.8 billion in the Base Case

## #4 Precedent Transactions

A set of U.S.-based software targets with LTM revenue between \$100 million and \$1 billion and revenue growth  $\geq 30\%$  implies a very wide range of values (\$2.4 to \$6.2 billion), but the most likely range is \$3 – 4 billion

## EXIT OPTION COMPARISON

## Strategic Alternatives for Centipede

The IPO is More Complex and Time-Consuming, But More Likely to Maximize Value

Both Cardinal's Offers Are 90% Stock, Which Removes Many Advantages of a Standard M&A Exit

	IPO	SPAC / Reverse Merger	Acquisition
Completion Time	▪ 6 – 12 months	▪ 2 – 3 months	▪ 6 – 12 months
Time to Sell Stake(s)	▪ Several Years	▪ Several Years	▪ Several Years (90% Stock)
Pricing Discount	▪ 10 – 20%	▪ N/A	▪ N/A
% Stake Sold	▪ 7 – 13%	▪ 8 – 15%	▪ 100% (Full Exit)
Valuation	▪ 3.5 – 6.5x CY 25 Revenue	▪ 3.5 – 6.5x CY 25 Revenue	▪ 3.3 – 5.0x CY 25 Revenue
Shareholder Conflicts	▪ None	▪ None	▪ Likely due to liq. pref. and participating pref.
Closing Probability	▪ Moderate	▪ Moderate	▪ High
Performance	▪ Median gain of 10 – 15% after 3 – 6 months since 2008 <sup>(1)</sup>	▪ Median 12-month return of (19%) for 2019 – 2020 cohort <sup>(2)</sup>	▪ N/A

(1) Source: <https://www.cnbc.com/2022/01/20/record-ipo-rush-of-2021-led-to-historically-dismal-returns-for-investors-with-no-relief-in-sight.html>

(2) Source: "A Sober Look at SPACs" ([https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3720919](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3720919))


## Valuation by Exit Strategy

Only the IPO and SPAC Options Value Centipede at Above-Market Rates

IPOs Are Traditionally Priced Based on Forward Multiples, Such As 2-Year Forward TEV / Revenue

- If both Earnouts are paid in full, Offer A values Centipede in-line with the multiples produced by the public comps and the implied DCF valuation in the Base Case<sup>(1)(2)</sup>
- If only the first Earnout is paid, Centipede's valuation would be significantly lower than the valuation methodology output<sup>(1)(2)</sup>
- Offer B offers a more certain outcome since there are no Earnouts (only a 5% Escrow), but also a valuation ~10% below the numbers implied by the other methodologies<sup>(1)(2)</sup>
- While the IPO valuation is more speculative, we believe that a 5.0x baseline 2-year forward revenue multiple is justified based on Centipede's above-market growth rates and favorable SaaS metrics

Implied CY 25 TEV / Revenue Multiples (Base Case)



Implied CY 25 TEV / Revenue Multiples (Base Case)




## SPAC / Reverse Merger vs. IPO Comparison

Both Options Offer Similar Headline Valuations, But Different Timing and Dilution


Given Centipede's Strong Growth Profile, an IPO is More Likely to Maximize Long-Term Value

- Both options create dilution due to the ~15% Pricing Discount in the IPO and the ~20% "Sponsor Promote" in the SPAC and reverse merger, but the SPAC creates more dilution since millions of shares are granted to the Sponsor for nearly \$0
- The main advantages of SPAC deals are speed, reduced complexity/regulation, and reduced uncertainty if a favorable SPAC Sponsor can be found
- Given Centipede's strong growth profile and industry-leading position, institutional interest in an IPO is likely to be high, reducing the traditional advantages of a SPAC

**SPAC Implied Ownership, Post-Warrants**



**IPO Implied Ownership, Post-Warrants**





# Summary of Merger Model Assumptions

Offer A	Offer B
<ul style="list-style-type: none"> <li>▪ \$3.0 billion; \$2.9 billion</li> </ul>	<ul style="list-style-type: none"> <li>▪ \$2.4 billion; \$2.3 billion</li> </ul>
<ul style="list-style-type: none"> <li>▪ 90% Stock; 10% Cash</li> </ul>	<ul style="list-style-type: none"> <li>▪ 90% Stock; 10% Cash</li> </ul>
<ul style="list-style-type: none"> <li>▪ 20% of Purchase TEV; 40% in Year 2 and 60% in Year 3</li> </ul>	<ul style="list-style-type: none"> <li>▪ None</li> </ul>
<ul style="list-style-type: none"> <li>▪ 7% Management Retention Pool and 10% Escrow</li> </ul>	<ul style="list-style-type: none"> <li>▪ 5% Escrow</li> </ul>
<ul style="list-style-type: none"> <li>▪ 100% Debt (10% Interest Rate and 5% Amortization)</li> </ul>	<ul style="list-style-type: none"> <li>▪ N/A</li> </ul>
<ul style="list-style-type: none"> <li>▪ Cash-Free/Debt-Free; \$140 million WC adjustment; \$100 million Minimum Cash</li> </ul>	
<ul style="list-style-type: none"> <li>▪ Revenue Synergies are 10% of Centipede's total sales; Expense Synergies are a 15% reduction in Centipede's G&amp;A expense with 2-year realization &amp; integration costs</li> </ul>	
<ul style="list-style-type: none"> <li>▪ Assumed</li> </ul>	<ul style="list-style-type: none"> <li>▪ Terminated</li> </ul>
<ul style="list-style-type: none"> <li>▪ \$1.2 billion in Other Intangibles; \$2.0 billion in Goodwill</li> </ul>	<ul style="list-style-type: none"> <li>▪ \$1.4 billion in Other Intangibles; \$1.4 billion in Goodwill</li> </ul>

Headline & Adjusted  
Purchase Ent. Value

Deal Financing

Earnouts

Other Deferred  
Payments

Earnout Financing

Cash, Debt, and  
Working Capital

Synergies

Unvested Options

Purchase Accounting

# Pro-Forma EPS Accretion / Dilution

The Deal is Highly Dilutive for the First Several Years Post-Close

## EPS Dynamics

- Because of the ~78x P/E multiple Cardinal is offering for Centipede, the deal is dilutive to Pro-Forma EPS until at least Year 3 with the “Offer A” assumptions
- The Offer B numbers are slightly less dilutive, but this offer may lead to shareholder conflicts and unsatisfied employees and managers at Centipede due to the termination of unvested options
- Debt is more expensive than Equity for Cardinal from an EPS perspective, and the company has minimal Cash, so alternate deal financing would not improve the picture
- Only substantially higher synergies, much higher growth rates, or a lower purchase price would change the numbers significantly

## Analysis Summary

### Offer A – Year 1 PF EPS Accretion/Dilution

Earnout %	Headline Purchase TEV		
	\$2.4B	\$3.0B	\$3.6B
35%	(34%)	(48%)	(60%)
20%	(39%)	(53%)	(65%)
0%	(45%)	(58%)	(69%)

### Offer A – Year 2 PF EPS Accretion/Dilution

Earnout %	Headline Purchase TEV		
	\$2.4B	\$3.0B	\$3.6B
35%	(22%)	(37%)	(50%)
20%	(27%)	(42%)	(55%)
0%	(34%)	(48%)	(60%)

### Offer B – Year 1 PF EPS Accretion/Dilution

Earnout %	Headline Purchase TEV		
	\$1.8B	\$2.4B	\$3.0B
0%	(4%)	(14%)	(22%)
0%	(4%)	(14%)	(22%)
0%	(4%)	(14%)	(22%)

### Offer B – Year 2 PF EPS Accretion/Dilution



Earnout %	Headline Purchase TEV		
	\$1.8B	\$2.4B	\$3.0B
0%	6%	(10%)	(16%)
0%	6%	(10%)	(16%)
0%	6%	(10%)	(16%)

# Revenue Growth & Financial Contribution Analysis

The Current Deal Benefits Cardinal More Than Centipede


## Growth Rate Impact

- Centipede's contributions boost Cardinal's growth rates from the 5 – 10% range to the 10 – 20% range
- Meanwhile, Centipede's standalone growth rates are significantly higher than the combined company's in the projected period:



## Contribution Analysis

- The ownership percentages are reasonable based on *just the upfront Stock consideration* for Offer A
- However, the ownership percentages look increasingly skewed into the projected years due to Centipede's higher long-term growth rates



# Earnout Treatment & Misaligned Incentives


Different Investor Groups Will Favor Offer A or B Based on Their Initial Deal Terms

(\$ in Millions USD)


## Investor Conflicts

- Because of the higher upfront consideration, most VC investor groups will prefer Offer B
- But the largest group of shareholders, the Series C investors, will be neutral because of their 2x liquidation preference; they earn \$680 million in either scenario
- The Series C firms invested \$340 million at a \$1.34 billion post-money valuation; a Series D “down round” at a \$756 million post-money valuation followed several years later, and both groups have 2x liquidation preferences
- The employees and management team will prefer Option A since Cardinal will assume unvested options; Offer B terminates all unvested options

**Offer A - Investor Proceeds (37% Deferred Payment)**



**Offer B - Investor Proceeds (5% Deferred Payment)**



## CONCLUSIONS

# Conclusions and Recommendations

Centipede is a Promising SaaS Company with High Growth Potential

A Traditional IPO is Most Likely to Maximize Long-Term Shareholder Value and Investor Proceeds

#1

Centipede's Current  
Valuation

Currently, Centipede is worth between \$2 and \$3 billion; Cardinal's offer values it appropriately only if both Earnouts are paid in full, but there is uncertainty over the Year 3 Earnout due to the aggressive EBITDA target

#2

IPO vs. SPAC vs.  
M&A Alternatives

An IPO or SPAC would produce a higher valuation for shareholders (3.5 – 6.5x CY 25 revenue); the time frame to exit would be slower, but since Cardinal's offer is 90% Stock, the M&A option is not necessarily much better in terms of time to exit

#3

Recommended  
Process and Timing

We recommend starting preparations for an IPO immediately, with an aim to go public in CY 24; the team can kick off a parallel process to locate an appropriate SPAC Sponsor as well

#4

Renegotiated  
Deal(s) with Cardinal

Given the EPS accretion/dilution and contribution numbers, Cardinal is unlikely to improve its offer substantially; however, if it could offer a slightly higher price under the Offer B deal terms, it might be worth re-engaging in targeted discussions